Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 551 entries
Sorted by: Best Match Show Resources per page
Novel autosomal recessive gene mutations in aquaporin-2 in two Chinese congenital nephrogenic diabetes insipidus pedigrees.

International journal of clinical and experimental medicine

Cen J, Nie M, Duan L, Gu F.
PMID: 26064258
Int J Clin Exp Med. 2015 Mar 15;8(3):3629-39. eCollection 2015.

Recent evidence has linked novel mutations in the arginine vasopressin receptor 2 gene (AVPR2) and aquaporin-2 gene (AQP2) present in Southeast Asian populations to congenital nephrogenic diabetes insipidus (NDI). To investigate mutations in 2 distinct Chinese pedigrees with NDI...

Cite
Cen J, Nie M, Duan L, et al. Novel autosomal recessive gene mutations in aquaporin-2 in two Chinese congenital nephrogenic diabetes insipidus pedigrees. Int J Clin Exp Med. 2015;8(3):3629-39
Cen, J., Nie, M., Duan, L., & Gu, F. (2015). Novel autosomal recessive gene mutations in aquaporin-2 in two Chinese congenital nephrogenic diabetes insipidus pedigrees. International journal of clinical and experimental medicine, 8(3), 3629-39.
Cen, Jing, et al. "Novel autosomal recessive gene mutations in aquaporin-2 in two Chinese congenital nephrogenic diabetes insipidus pedigrees." International journal of clinical and experimental medicine vol. 8,3 (2015): 3629-39.
Cen J, Nie M, Duan L, Gu F. Novel autosomal recessive gene mutations in aquaporin-2 in two Chinese congenital nephrogenic diabetes insipidus pedigrees. Int J Clin Exp Med. 2015 Mar 15;8(3):3629-39. eCollection 2015. PMID: 26064258; PMCID: PMC4443092.
Copy Download .nbib Format: NLM
Coagulopathy of Liver Disease.

Current treatment options in gastroenterology

Kaul V, Munoz SJ.
PMID: 11096602
Curr Treat Options Gastroenterol. 2000 Dec;3(6):433-438. doi: 10.1007/s11938-000-0030-y.

Coagulopathy in patients with liver disease results from impairments in the clotting and fibrinolytic systems, as well as from reduced number and function of platelets. Parenteral vitamin K replacement corrects coagulopathy related to biliary obstruction, bacterial overgrowth, or malnutrition....

Cite
Kaul V, Munoz SJ. Coagulopathy of Liver Disease. Curr Treat Options Gastroenterol. 2000;3(6):433-438doi: 10.1007/s11938-000-0030-y.
Kaul, V., & Munoz, S. J. (2000). Coagulopathy of Liver Disease. Current treatment options in gastroenterology, 3(6), 433-438. https://doi.org/10.1007/s11938-000-0030-y
Kaul, and Munoz. "Coagulopathy of Liver Disease." Current treatment options in gastroenterology vol. 3,6 (2000): 433-438. doi: https://doi.org/10.1007/s11938-000-0030-y
Kaul V, Munoz SJ. Coagulopathy of Liver Disease. Curr Treat Options Gastroenterol. 2000 Dec;3(6):433-438. doi: 10.1007/s11938-000-0030-y. PMID: 11096602.
Copy Download .nbib Format: NLM
Vascular Effects of Progesterone : Role of Cellular Calcium Regulation.

Hypertension (Dallas, Tex. : 1979)

Barbagallo M, Dominguez LJ, Licata G, Shan J, Bing L, Karpinski E, Pang PK, Resnick LM.
PMID: 11208769
Hypertension. 2001 Jan;37(1):142-147. doi: 10.1161/01.hyp.37.1.142.

-Vascular actions of progesterone have been reported, independently of estrogen, affecting both blood pressure and other aspects of the cardiovascular system. To study possible mechanisms underlying these effects, we examined the effects of P in vivo in intact rats...

Cite
Barbagallo M, Dominguez LJ, Licata G, et al. Vascular Effects of Progesterone : Role of Cellular Calcium Regulation. Hypertension. 2001;37(1):142-147doi: 10.1161/01.hyp.37.1.142.
Barbagallo, M., Dominguez, L. J., Licata, G., Shan, J., Bing, L., Karpinski, E., Pang, P. K., & Resnick, L. M. (2001). Vascular Effects of Progesterone : Role of Cellular Calcium Regulation. Hypertension (Dallas, Tex. : 1979), 37(1), 142-147. https://doi.org/10.1161/01.hyp.37.1.142
Barbagallo, Mario, et al. "Vascular Effects of Progesterone : Role of Cellular Calcium Regulation." Hypertension (Dallas, Tex. : 1979) vol. 37,1 (2001): 142-147. doi: https://doi.org/10.1161/01.hyp.37.1.142
Barbagallo M, Dominguez LJ, Licata G, Shan J, Bing L, Karpinski E, Pang PK, Resnick LM. Vascular Effects of Progesterone : Role of Cellular Calcium Regulation. Hypertension. 2001 Jan;37(1):142-147. doi: 10.1161/01.hyp.37.1.142. PMID: 11208769.
Copy Download .nbib Format: NLM
SCN-AVP release of mPer1/mPer2 double-mutant mice in vitro.

Journal of circadian rhythms

van der Veen DR, Mulder EG, Oster H, Gerkema MP, Hut RA.
PMID: 18355404
J Circadian Rhythms. 2008 Mar 20;6:5. doi: 10.1186/1740-3391-6-5.

BACKGROUND: Circadian organisation of behavioural and physiological rhythms in mammals is largely driven by the clock in the suprachiasmatic nuclei (SCN) of the hypothalamus. In this clock, a molecular transcriptional repression and activation mechanism generates near 24 hour rhythms....

Cite
van der Veen DR, Mulder EG, Oster H, et al. SCN-AVP release of mPer1/mPer2 double-mutant mice in vitro. J Circadian Rhythms. 2008;6:5doi: 10.1186/1740-3391-6-5.
van der Veen, D. R., Mulder, E. G., Oster, H., Gerkema, M. P., & Hut, R. A. (2008). SCN-AVP release of mPer1/mPer2 double-mutant mice in vitro. Journal of circadian rhythms, 65. https://doi.org/10.1186/1740-3391-6-5
van der Veen, Daan R, et al. "SCN-AVP release of mPer1/mPer2 double-mutant mice in vitro." Journal of circadian rhythms vol. 6 (2008): 5. doi: https://doi.org/10.1186/1740-3391-6-5
van der Veen DR, Mulder EG, Oster H, Gerkema MP, Hut RA. SCN-AVP release of mPer1/mPer2 double-mutant mice in vitro. J Circadian Rhythms. 2008 Mar 20;6:5. doi: 10.1186/1740-3391-6-5. PMID: 18355404; PMCID: PMC2277380.
Copy Download .nbib Format: NLM
Conivaptan: a step forward in the treatment of hyponatremia?.

Therapeutics and clinical risk management

Hline SS, Pham PT, Pham PT, Aung MH, Pham PM, Pham PC.
PMID: 18728836
Ther Clin Risk Manag. 2008 Apr;4(2):315-26. doi: 10.2147/tcrm.s340.

Hyponatremia is one of the most common electrolyte abnormalities linked to adverse outcomes and increased mortality in hospitalized patients. While the differential diagnosis for hyponatremia is diverse, most cases stem from arginine vasopressin (AVP) dysregulation, where hypoosmolality fails to...

Cite
Hline SS, Pham PT, Pham PT, et al. Conivaptan: a step forward in the treatment of hyponatremia?. Ther Clin Risk Manag. 2008;4(2):315-26doi: 10.2147/tcrm.s340.
Hline, S. S., Pham, P. T., Pham, P. T., Aung, M. H., Pham, P. M., & Pham, P. C. (2008). Conivaptan: a step forward in the treatment of hyponatremia?. Therapeutics and clinical risk management, 4(2), 315-26. https://doi.org/10.2147/tcrm.s340
Hline, Su Su, et al. "Conivaptan: a step forward in the treatment of hyponatremia?." Therapeutics and clinical risk management vol. 4,2 (2008): 315-26. doi: https://doi.org/10.2147/tcrm.s340
Hline SS, Pham PT, Pham PT, Aung MH, Pham PM, Pham PC. Conivaptan: a step forward in the treatment of hyponatremia?. Ther Clin Risk Manag. 2008 Apr;4(2):315-26. doi: 10.2147/tcrm.s340. PMID: 18728836; PMCID: PMC2504060.
Copy Download .nbib Format: NLM
Bacitracin significantly reduces degradation of peptides in plant cell cultures.

Biotechnology and bioengineering

Bateman KS, Congiu M, Tregear GW, Clarke AE, Anderson MA.
PMID: 18633969
Biotechnol Bioeng. 1997 Jan 20;53(2):226-31. doi: 10.1002/(SICI)1097-0290(19970120)53:2<226::AID-BIT14>3.0.CO;2-I.

Production of useful peptides using recombinant plant cells is often limited by the stability of the newly translated peptides in the plant expression system. As an initial step toward producing peptides in transformed plant cell cultures, we examined the...

Cite
Bateman KS, Congiu M, Tregear GW, et al. Bacitracin significantly reduces degradation of peptides in plant cell cultures. Biotechnol Bioeng. 1997;53(2):226-31doi: 10.1002/(SICI)1097-0290(19970120)53:2<226::AID-BIT14>3.0.CO;2-I.
Bateman, K. S., Congiu, M., Tregear, G. W., Clarke, A. E., & Anderson, M. A. (1997). Bacitracin significantly reduces degradation of peptides in plant cell cultures. Biotechnology and bioengineering, 53(2), 226-31. https://doi.org/10.1002/(SICI)1097-0290(19970120)53:2<226::AID-BIT14>3.0.CO;2-I
Bateman, K S, et al. "Bacitracin significantly reduces degradation of peptides in plant cell cultures." Biotechnology and bioengineering vol. 53,2 (1997): 226-31. doi: https://doi.org/10.1002/(SICI)1097-0290(19970120)53:2<226::AID-BIT14>3.0.CO;2-I
Bateman KS, Congiu M, Tregear GW, Clarke AE, Anderson MA. Bacitracin significantly reduces degradation of peptides in plant cell cultures. Biotechnol Bioeng. 1997 Jan 20;53(2):226-31. doi: 10.1002/(SICI)1097-0290(19970120)53:2<226::AID-BIT14>3.0.CO;2-I. PMID: 18633969.
Copy Download .nbib Format: NLM
Arginine vasopressin as a rescue vasopressor agent in the operating room.

Current opinion in anaesthesiology

Jochberger S, Wenzel V, Dünser MW.
PMID: 16534265
Curr Opin Anaesthesiol. 2005 Aug;18(4):396-404. doi: 10.1097/01.aco.0000174963.35877.81.

PURPOSE OF REVIEW: This review gives an overview of the current knowledge and research on the use of arginine vasopressin in cardiac arrest and severe shock states.RECENT FINDINGS: Animal models have revealed the effectiveness of arginine vasopressin in increasing...

Cite
Jochberger S, Wenzel V, Dünser MW. Arginine vasopressin as a rescue vasopressor agent in the operating room. Curr Opin Anaesthesiol. 2005;18(4):396-404doi: 10.1097/01.aco.0000174963.35877.81.
Jochberger, S., Wenzel, V., & Dünser, M. W. (2005). Arginine vasopressin as a rescue vasopressor agent in the operating room. Current opinion in anaesthesiology, 18(4), 396-404. https://doi.org/10.1097/01.aco.0000174963.35877.81
Jochberger, Stefan, et al. "Arginine vasopressin as a rescue vasopressor agent in the operating room." Current opinion in anaesthesiology vol. 18,4 (2005): 396-404. doi: https://doi.org/10.1097/01.aco.0000174963.35877.81
Jochberger S, Wenzel V, Dünser MW. Arginine vasopressin as a rescue vasopressor agent in the operating room. Curr Opin Anaesthesiol. 2005 Aug;18(4):396-404. doi: 10.1097/01.aco.0000174963.35877.81. PMID: 16534265.
Copy Download .nbib Format: NLM
Genetic basis of familial neurohypophyseal diabetes insipidus.

Trends in endocrinology and metabolism: TEM

Hansen LK, Rittig S, Robertson GL.
PMID: 18406826
Trends Endocrinol Metab. 1997 Nov;8(9):363-72. doi: 10.1016/s1043-2760(97)00157-4.

Familial neurohypophyseal diabetes insipidus (FNDI) is an autosomal dominant (adFNDI) or X-linked recessive (xrFNDI) disorder characterized by the development in early childhood of an irreversible deficiency of arginine vasopressin (AVP) secretion. Autopsy data in adFNDI reveal selective destruction of...

Cite
Hansen LK, Rittig S, Robertson GL. Genetic basis of familial neurohypophyseal diabetes insipidus. Trends Endocrinol Metab. 1997;8(9):363-72doi: 10.1016/s1043-2760(97)00157-4.
Hansen, L. K., Rittig, S., & Robertson, G. L. (1997). Genetic basis of familial neurohypophyseal diabetes insipidus. Trends in endocrinology and metabolism: TEM, 8(9), 363-72. https://doi.org/10.1016/s1043-2760(97)00157-4
Hansen, L K, et al. "Genetic basis of familial neurohypophyseal diabetes insipidus." Trends in endocrinology and metabolism: TEM vol. 8,9 (1997): 363-72. doi: https://doi.org/10.1016/s1043-2760(97)00157-4
Hansen LK, Rittig S, Robertson GL. Genetic basis of familial neurohypophyseal diabetes insipidus. Trends Endocrinol Metab. 1997 Nov;8(9):363-72. doi: 10.1016/s1043-2760(97)00157-4. PMID: 18406826.
Copy Download .nbib Format: NLM
Corticotropin-release inhibitory factor Evidence for dual stimulatory and inhibitory hypothalamic regulation over adrenocorticotropin secretion and biosynthesis.

Trends in endocrinology and metabolism: TEM

Engler D, Liu JP, Clarke IJ, Funder JW.
PMID: 18407219
Trends Endocrinol Metab. 1994 Sep;5(7):272-83. doi: 10.1016/1043-2760(94)p3202-i.

The hypothalamus is currently thought to stimulate the synthesis and secretion of ACTH uniquely by secreting neuropeptides into the hypophysial-portal circulation, of which the most important are CRH and arginine vasopressin. However, analysis of the effects of pituitary isolation...

Cite
Engler D, Liu JP, Clarke IJ, et al. Corticotropin-release inhibitory factor Evidence for dual stimulatory and inhibitory hypothalamic regulation over adrenocorticotropin secretion and biosynthesis. Trends Endocrinol Metab. 1994;5(7):272-83doi: 10.1016/1043-2760(94)p3202-i.
Engler, D., Liu, J. P., Clarke, I. J., & Funder, J. W. (1994). Corticotropin-release inhibitory factor Evidence for dual stimulatory and inhibitory hypothalamic regulation over adrenocorticotropin secretion and biosynthesis. Trends in endocrinology and metabolism: TEM, 5(7), 272-83. https://doi.org/10.1016/1043-2760(94)p3202-i
Engler, D, et al. "Corticotropin-release inhibitory factor Evidence for dual stimulatory and inhibitory hypothalamic regulation over adrenocorticotropin secretion and biosynthesis." Trends in endocrinology and metabolism: TEM vol. 5,7 (1994): 272-83. doi: https://doi.org/10.1016/1043-2760(94)p3202-i
Engler D, Liu JP, Clarke IJ, Funder JW. Corticotropin-release inhibitory factor Evidence for dual stimulatory and inhibitory hypothalamic regulation over adrenocorticotropin secretion and biosynthesis. Trends Endocrinol Metab. 1994 Sep;5(7):272-83. doi: 10.1016/1043-2760(94)p3202-i. PMID: 18407219.
Copy Download .nbib Format: NLM
Molecular characterization of nephrogenic diabetes insipidus.

Trends in endocrinology and metabolism: TEM

Knoers NV.
PMID: 18407239
Trends Endocrinol Metab. 1994 Dec;5(10):422-8. doi: 10.1016/1043-2760(95)92525-n.

Nephrogenic diabetes insipidus (NDI) is characterized by insensitivity of the distal renal nephron to the antidiuretic effect of the neurohypophyseal hormone arginine vasopressin. In the last 2 years, two different genetic defects causing the NDI phenotype have been identified....

Cite
Knoers NV. Molecular characterization of nephrogenic diabetes insipidus. Trends Endocrinol Metab. 1994;5(10):422-8doi: 10.1016/1043-2760(95)92525-n.
Knoers, N. V. (1994). Molecular characterization of nephrogenic diabetes insipidus. Trends in endocrinology and metabolism: TEM, 5(10), 422-8. https://doi.org/10.1016/1043-2760(95)92525-n
Knoers, N V. "Molecular characterization of nephrogenic diabetes insipidus." Trends in endocrinology and metabolism: TEM vol. 5,10 (1994): 422-8. doi: https://doi.org/10.1016/1043-2760(95)92525-n
Knoers NV. Molecular characterization of nephrogenic diabetes insipidus. Trends Endocrinol Metab. 1994 Dec;5(10):422-8. doi: 10.1016/1043-2760(95)92525-n. PMID: 18407239.
Copy Download .nbib Format: NLM
Structural organization of the rat gene for the arginine vasopressin-neurophysin precursor.

The EMBO journal

[No authors listed]
PMID: 16453455
EMBO J. 1983;2(6):1015.

[This corrects the article on p. 763 in vol. 2, PMID: 6315416.].

Cite
Structural organization of the rat gene for the arginine vasopressin-neurophysin precursor. EMBO J. 1983;2(6):1015
(1983). Structural organization of the rat gene for the arginine vasopressin-neurophysin precursor. The EMBO journal, 2(6), 1015.
"Structural organization of the rat gene for the arginine vasopressin-neurophysin precursor." The EMBO journal vol. 2,6 (1983): 1015.
Structural organization of the rat gene for the arginine vasopressin-neurophysin precursor. EMBO J. 1983;2(6):1015. PMID: 16453455; PMCID: PMC555223.
Copy Download .nbib Format: NLM
Tolvaptan for the treatment of hyponatremia and congestive heart failure.

Future cardiology

Orlandi C, Zimmer CA, Gheorghiade M.
PMID: 19804253
Future Cardiol. 2006 Nov;2(6):627-34. doi: 10.2217/14796678.2.6.627.

Tolvaptan is an oral, once-daily nonpeptide arginine vasopressin V(2)-receptor antagonist under development for the treatment of hyponatremia and congestive heart failure. In Phase II clinical trials, tolvaptan, in addition to standard therapy, increased fluid loss, resulting in decreased body...

Cite
Orlandi C, Zimmer CA, Gheorghiade M. Tolvaptan for the treatment of hyponatremia and congestive heart failure. Future Cardiol. 2006;2(6):627-34doi: 10.2217/14796678.2.6.627.
Orlandi, C., Zimmer, C. A., & Gheorghiade, M. (2006). Tolvaptan for the treatment of hyponatremia and congestive heart failure. Future cardiology, 2(6), 627-34. https://doi.org/10.2217/14796678.2.6.627
Orlandi, Cesare, et al. "Tolvaptan for the treatment of hyponatremia and congestive heart failure." Future cardiology vol. 2,6 (2006): 627-34. doi: https://doi.org/10.2217/14796678.2.6.627
Orlandi C, Zimmer CA, Gheorghiade M. Tolvaptan for the treatment of hyponatremia and congestive heart failure. Future Cardiol. 2006 Nov;2(6):627-34. doi: 10.2217/14796678.2.6.627. PMID: 19804253.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 551 entries